Drugging the p53 pathway: Understanding the route to clinical efficacy

Nature Reviews Drug Discovery

Volumn 13, Issue 3, 2014, Pages 217-236

  Hoe, Khoo Kian ^a   Verma, Chandra S ^b,c   Lane, David P ^c  

^a AGENCY FOR SCIENCE   (Singapore)

^b BIOINFORMATICS INSTITUTE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APR 246; CYTARABINE; DASATINIB; DOXORUBICIN; DS 3032B; MI 773; NAVITOCLAX; PRIMA 1; PROTEIN MDM2; PROTEIN P53; RG 7112; RO 5503781; SORAFENIB; UNCLASSIFIED DRUG; ZINC;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL FATE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; DOWN REGULATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION REGULATION; GENETIC MODEL; HEMATOLOGIC MALIGNANCY; HUMAN; LIPOSARCOMA; LUNG SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895779578     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4236     Document Type: Review

References (240)

1. Lane, D. P. & Verma, C. Mdm2 in evolution. Genes Cancer 3, 320-324 (2012
2. Hock, A. & Vousden, K. H. Regulation of the p53 pathway by ubiquitin and related proteins. Int. J. Biochem. Cell Biol. 42, 1618-1621 (2010
3. Huang, L. et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc. Natl Acad. Sci. USA 108, 12001-12006 (2011
4. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000
5. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004
6. MacCallum, D. E. et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 13, 2575-2587 (1996
7. Komarova, E. A. et al. Transgenic mice with p53 responsive lacZ: 53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16, 1391-1400 (1997
8. Christophorou, MOA., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53 mediated tumour suppression. Nature 443, 214-217 (2006
9. Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B. & Evan, G. I. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501-514 (2006
10. Mendrysa, S. M. & Perry, M. E. Tumor suppression by p53 without accelerated aging: Just enough of a good thing? Cell Cycle 5, 714-717 (2006
11. Mendrysa, S. M. et al. Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 23, 462-472 (2003
12. Bond, G. L. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004
13. Garcia-Cao, I. et al. Super p53 mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21, 6225-6235 (2002
14. Efeyan, A., Garcia-Cao, I., Herranz, D., Velasco-Miguel, S. & Serrano, M. Tumour biology: Policing of oncogene activity by p53. Nature 443, 159 (2006
15. Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006
16. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007
17. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007
18. Li, T. et al. Tumor suppression in the absence of p53 mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283 (2012
19. Brady, C. A. et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571-583 (2011
20. Jiang, D. et al. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc. Natl Acad. Sci. USA 108, 17123-17128 (2011
21. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J. & Leder, P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995
22. Villunger, A. et al. p53-And drug-induced apoptotic responses mediated by BH3 only proteins Puma and Noxa. Science 302, 1036-1038 (2003
23. Valente, L. J. et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 3, 1339-1345 (2013
24. Sablina, A. A. et al. The antioxidant function of the p53 tumor suppressor. Nature Med. 11, 1306-1313 (2005
25. Robertson, K. D. & Jones, P. A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-Type p53. Mol. Cell. Biol. 18, 6457-6473 (1998
26. Roxburgh, P. et al. Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis 33, 791-798 (2012
27. Li, C. & Johnson, D. E. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. Cell Cycle 12, 923-934 (2013
28. Kitagaki, J., Agama, K. K., Pommier, Y., Yang, Y. & Weissman, A. M. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol. Cancer Ther. 7, 2445-2454 (2008
29. Lain, S. et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13, 454-463 (2008
30. Brachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P. & Boeke, J. D. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17, 1847-1859 (1998
31. Nikolova, P. V., Wong, K. B., DeDecker, B., Henckel, J. & Fersht, A. R. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19, 370-378 (2000
32. Petitjean, A. et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622-629 (2007
33. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R. & Lane, D. P. Awakening guardian angels: Drugging the p53 pathway. Nature Rev. Cancer 9, 862-873 (2009
34. Cheok, C. F., Verma, C. S., Baselga, J. & Lane, D. P. Translating p53 into the clinic. Nature Rev. Clin. Oncol. 8, 25-37 (2011
35. Picksley, S. M., Vojtesek, B., Sparks, A. & Lane, D. P. Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9, 2523-2529 (1994
36. Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996
37. Bottger, A. et al. Design of a synthetic Mdm2 binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860-869 (1997
38. Chene, P. et al. A small synthetic peptide, which inhibits the p53 hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. 299, 245-253 (2000
39. Wang, S., Zhao, Y., Bernard, D., Aguilar, A. & Kumar, S. in Protein-Protein Interactions Vol. 8 (ed. Wendt, M. D.) 57-79 (Springer, 2012
40. Grasberger, B. L. et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 48, 909-912 (2005
41. Allen, J. G. et al. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-Tumor protein 53 protein-protein interaction. J. Med. Chem. 52, 7044-7053 (2009
42. Orner, B. P., Ernst, J. T. & Hamilton, A. D. Toward proteomimetics: Terphenyl derivatives as structural and functional mimics of extended regions of an α helix. J. Am. Chem. Soc. 123, 5382-5383 (2001
43. Yin, H. et al. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew. Chem. Int. Ed. Engl. 44, 2704-2707 (2005
44. Go, M. L., Wu, X. & Liu, X. L. Chalcones: An update on cytotoxic and chemoprotective properties. Curr. Med. Chem. 12, 483-499 (2005
45. Stoll, R. et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40, 336-344 (2001
46. Shangary, S. et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl Acad. Sci. USA 105, 3933-3938 (2008
47. Zhao, Y. et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI 888) achieved complete and durable tumor regression in mice. J. Med. Chem. 56, 5553-5561 (2013
48. Czarna, A. et al. Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: 53/Hdm2 antagonists. Angew. Chem. Int. Ed. 49, 5352-5356 (2010
49. Boettcher, A. et al. 3 imidazolyl-indoles for the treatment of proliferative diseases. WO Patent 2008119741 (2008
50. Hardcastle, I. R. et al. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: Structure-Activity studies leading to improved potency. J. Med. Chem. 54, 1233-1243 (2011
51. Burdack, C. et al. HDM2 ligands. WO Patent 2010028862 (2010
52. Essmann, F. & Schulze-Osthoff, K. Translational approaches targeting the p53 pathway for anti-cancer therapy. Br. J. Pharmacol. 165, 328-344 (2012
53. Bogen, S. L. et al. Substituted piperidines that increase P53 activity and the uses thereof. WO Patent 2011046771A1 (2011
54. Bertamino, A. et al. Synthesis, in vitro, and in cell studies of a new series of [indoline 3,2Ŷ thiazolidine]-based p53 modulators. J. Med. Chem. 56, 5407-5421 (2013
55. Galatin, P. S. & Abraham, D. J. A nonpeptidic sulfonamide inhibits the p53 mdm2 interaction and activates p53 dependent transcription in mdm2 overexpressing cells. J. Med. Chem. 47, 4163-4165 (2004
56. Rew, Y. et al. Structure-based design of novel inhibitors of the MDM2-p53 interaction. J. Med. Chem. 55, 4936-4954 (2012
57. Gonzalez-Lopez de Turiso, F. et al. Rational design and binding mode duality of MDM2-p53 inhibitors. J. Med. Chem. 56, 4053-4070 (2013
58. Lucas, B. S. et al. An expeditious synthesis of the MDM2-p53 inhibitor AM 8553. J. Am. Chem. Soc. 134, 12855-12860 (2012
59. Riedinger, C. et al. Understanding small-molecule binding to MDM2: Insights into structural effects of isoindolinone inhibitors from NMR spectroscopy. Chem. Biol. Drug Design 77, 301-308 (2011
60. Michelsen, K. et al. Ordering of the N terminus of human MDM2 by small molecule inhibitors. J. Am. Chem. Soc. 134, 17059-17067 (2012
61. Wei, S. J. et al. In vitro selection of mutant HDM2 resistant to Nutlin inhibition. PLoS ONE 8, e62564 (2013
62. Vu, B. et al. Discovery of RG7112: A small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett. 4, 466-469 (2013
63. Ding, Q. et al. Discovery of RG7388, a potent and selective p53 MDM2 inhibitor in clinical development. J. Med. Chem. 56, 5979-5983 (2013
64. Wade, M. & Wahl, G. M. Targeting Mdm2 and Mdmx in cancer therapy: Better living through medicinal chemistry? Mol. Cancer Res. 7, 1-11 (2009
65. Gembarska, A. et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nature Med. 18, 1239-1247 (2012
66. Lu, M. et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1 phosphorylated nuclear iASPP. Cancer Cell 23, 618-633 (2013
67. van Leeuwen, I. M. et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 10, 1590-1598 (2011
68. Leo, M. et al. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. Biochem. Pharmacol. 85, 1234-1245 (2013
69. Nakamura, Y. et al. Siladenoserinols A-L: New sulfonated serinol derivatives from a tunicate as inhibitors of p53-Hdm2 interaction. Org. Lett. 15, 322-325 (2012
70. Reed, D. et al. Identification and characterization of the first small molecule inhibitor of MDMX. J. Biol. Chem. 285, 10786-10796 (2010
71. Noguchi, T. et al. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: Identification of novel peptidic inhibitors. Bioorg. Med. Chem. Lett. 23, 3802-3805 (2013
72. Graves, B. et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc. Natl Acad. Sci. USA 109, 11788-11793 (2012
73. ElSawy, K. M. et al. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study. Cell Cycle 12, 394-404 (2013
74. Hernychova, L. et al. Identification of a second Nutlin 3 responsive interaction site in the N terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry. Proteomics 13, 2512-2525 (2013
75. Pazgier, M. et al. Structural basis for high-Affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl Acad. Sci. USA 106, 4665-4670 (2009
76. Phan, J. et al. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J. Biol. Chem. 285, 2174-2183 (2010
77. Li, C. et al. Systematic mutational analysis of peptide inhibition of the p53 MDM2/MDMX interactions. J. Mol. Biol. 398, 200-213 (2010
78. Liu, M. et al. D peptide inhibitors of the p53 MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc. Natl Acad. Sci. USA 107, 14321-14326 (2010
79. Dastidar, S. G., Lane, D. P. & Verma, C. S. Multiple peptide conformations give rise to similar binding affinities: Molecular simulations of p53 MDM2. J. Am. Chem. Soc. 130, 13514-13515 (2008
80. Brown, C. J. et al. C terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms. PLoS ONE 6, e24122 (2011
81. Zhou, W. et al. Improved eIF4E binding peptides by phage display guided design: Plasticity of interacting surfaces yield collective effects. PLoS ONE 7, e47235 (2012
82. Schafmeister, C. E., Po, J. & Verdine, G. L. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122, 5891-5892 (2000
83. Bernal, F., Tyler, A. F., Korsmeyer, S. J., Walensky, L. D. & Verdine, G. L. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 129, 2456-2457 (2007
84. Bernal, F. et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18, 411-422 (2010
85. Brown, C. J. et al. Stapled peptides with improved potency and specificity that activate p53. ACS Chem. Biol. 8, 506-512 (2013
86. Chang, Y. S. et al. Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53 dependent cancer therapy. Proc. Natl Acad. Sci. USA 110, E3445-E3454 (2013
87. Brown, Z. Z. et al. A spiroligomer alpha-helix mimic that binds HDM2, penetrates human cells and stabilizes HDM2 in cell culture. PLoS ONE 7, e45948 (2012
88. Ji, Y. et al. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J. Am. Chem. Soc. 135, 11623-11633 (2013
89. Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004
90. Walensky, L. D. et al. A stapled BID BH3 helix directly binds and activates BAX. Mol. Cell 24, 199-210 (2006
91. Okamoto, T. et al. Stabilizing the pro-Apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. ACS Chem. Biol. 8, 297-302 (2013
92. Khoo, K. H., Andreeva, A. & Fersht, A. R. Adaptive evolution of p53 thermodynamic stability. J. Mol. Biol. 393, 161-175 (2009
93. Joerger, A. C. & Fersht, A. R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557-582 (2008
94. Sawkar, A. R. et al. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: A therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci. USA 99, 15428-15433 (2002
95. Sawkar, A. R. et al. Gaucher disease-Associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem. Biol. 12, 1235-1244 (2005
96. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013
97. Boeckler, F. M. et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl Acad. Sci. USA 105, 10360-10365 (2008
98. Wilcken, R. et al. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J. Am. Chem. Soc. 134, 6810-6818 (2012
99. Liu, X. et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 41, 6034-6044 (2013
100. Basse, N. et al. Toward the rational design of p53 stabilizing drugs: Probing the surface of the oncogenic Y220C mutant. Chem. Biol. 17, 46-56 (2010
101. Bykov, V. J. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med. 8, 282-288 (2002
102. Zache, N., Lambert, J. M., Wiman, K. G. & Bykov, V. J. PRIMA 1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol. 30, 411-418 (2008
103. Zandi, R. et al. PRIMA 1Met/APR 246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin. Cancer Res. 17, 2830-2841 (2011
104. Lehmann, S. et al. Targeting p53 in vivo: A first in human study with p53 targeting compound APR 246 in refractory hematologic malignancies and prostate cancer. J. Clin. Oncol. 30, 3633-3639 (2012
105. Lambert, J. M. et al. PRIMA 1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15, 376-388 (2009
106. Kaar, J. L. et al. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. Protein Sci. 19, 2267-2278 (2010
107. Wassman, C. D. et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nature Commun. 4, 1407 (2013
108. Scotcher, J. et al. Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry. J. Am. Soc. Mass Spectrom. 22, 888-897 (2011
109. Held, J. M. et al. Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach. Mol. Cell Proteom. 9, 1400-1410 (2010
110. Shalom-Feuerstein, R. et al. Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR 246/PRIMA 1MET. Proc. Natl Acad. Sci. USA 110, 2152-2156 (2013
111. Shen, J. et al. APR 246/PRIMA 1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations. Proc. Natl Acad. Sci. USA 110, 2157-2162 (2013
112. Rokaeus, N. et al. PRIMA 1(MET)/APR 246 targets mutant forms of p53 family members p63 and p73. Oncogene 29, 6442-6451 (2010
113. Stegh, A. H. Targeting the p53 signaling pathway in cancer therapy-The promises, challenges and perils. Expert Opin. Ther. Targets 16, 67-83 (2012
114. Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355 (1994
115. Loh, S. N. The missing zinc: P53 misfolding and cancer. Metallomics 2, 442-449 (2010
116. Joerger, A. C. & Fersht, A. R. Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 26, 2226-2242 (2007
117. Puca, R., Nardinocchi, L., Givol, D. & D'Orazi, G. Regulation of p53 activity by HIPK2: Molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 29, 4378-4387 (2010
118. Puca, R. et al. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 10, 1679-1689 (2011
119. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53 HDM 2 interaction and activates p53 function in tumors. Nature Med. 10, 1321-1328 (2004
120. Azmi, A. S. et al. MI 219 zinc combination: A new paradigm in MDM2 inhibitor-based therapy. Oncogene 30, 117-126 (2011
121. Yu, X., Vazquez, A., Levine, A. J. & Carpizo, D. R. Allele-specific p53 mutant reactivation. Cancer Cell 21, 614-625 (2012
122. Linde, L. & Kerem, B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet. 24, 552-563 (2008
123. Rowe, S. M. & Clancy, J. P. Pharmaceuticals targeting nonsense mutations in genetic diseases: Progress in development. BioDrugs 23, 165-174 (2009
124. Floquet, C., Deforges, J., Rousset, J. P. & Bidou, L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res. 39, 3350-3362 (2011
125. Sermet-Gaudelus, I. et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 182, 1262-1272 (2010
126. Kerem, E. et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. Lancet 372, 719-727 (2008
127. Auld, D. S. et al. Molecular basis for the high-Affinity binding and stabilization of firefly luciferase by PTC124. Proc. Natl Acad. Sci. USA 107, 4878-4883 (2010
128. Auld, D. S., Thorne, N., Maguire, W. F. & Inglese, J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc. Natl Acad. Sci. USA 106, 3585-3590 (2009
129. Kayali, R. et al. Read-Through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum. Mol. Genet. 21, 4007-4020 (2012
130. Choong, M. L., Yang, H., Lee, M. A. & Lane, D. P. Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy. Cell Cycle 8, 2810-2818 (2009
131. MacCallum, D. E. et al. Seliciclib (CYC202, R roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II dependent transcription and down-regulation of Mcl 1. Cancer Res. 65, 5399-5407 (2005
132. Smart, P. et al. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18, 7378-7386 (1999
133. Blank, J. L. et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8 activating enzyme inhibitor MLN4924. Cancer Res. 73, 225-234 (2013
134. Li, L. et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266-281 (2012
135. Rigatti, M. J., Verma, R., Belinsky, G. S., Rosenberg, D. W. & Giardina, C. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Mol. Carcinog. 51, 363-378 (2012
136. Verma, R., Rigatti, M. J., Belinsky, G. S., Godman, C. A. & Giardina, C. DNA damage response to the Mdm2 inhibitor nutlin 3. Biochem. Pharmacol. 79, 565-574 (2010
137. Secchiero, P. et al. The MDM 2 antagonist nutlin 3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia 9, 853-861 (2007
138. Shin, J. S. et al. Structural insights into the dual-Targeting mechanism of Nutlin 3. Biochem. Biophys. Res. Commun. 420, 48-53 (2012
139. Long, J. et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 116, 71-80 (2010
140. Secchiero, P. et al. Functional integrity of the p53 mediated apoptotic pathway induced by the nongenotoxic agent nutlin 3 in B cell chronic lymphocytic leukemia (B CLL). Blood 107, 4122-4129 (2006
141. Saha, M. N., Jiang, H. & Chang, H. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: Evidence for p53 transcription-dependent and-independent pathways. Cancer Biol. Ther. 10, 567-578 (2010
142. Van Maerken, T. et al. Antitumor activity of the selective MDM2 antagonist nutlin 3 against chemoresistant neuroblastoma with wild-Type p53. J. Natl Cancer Inst. 101, 1562-1574 (2009
143. Tabe, Y. et al. MDM2 antagonist nutlin 3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin. Cancer Res. 15, 933-942 (2009
144. Momand, J., Jung, D., Wilczynski, S. & Niland, J. The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459 (1998
145. Ohnstad, H. O. et al. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer 119, 1013-1022 (2013
146. Tovar, C. et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc. Natl Acad. Sci. USA 103, 1888-1893 (2006
147. Paris, R., Henry, R. E., Stephens, S. J., McBryde, M. & Espinosa, J. M. Multiple p53 independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 7, 2427-2433 (2008
148. Gutekunst, M. et al. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS ONE 6, e19198 (2011
149. Gutekunst, M. et al. Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct 4. Cancer Res. 73, 1460-1469 (2013
150. Ross, C. J. et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genet. 41, 1345-1349 (2009
151. Kracikova, M., Akiri, G., George, A., Sachidanandam, R. & Aaronson, S. A. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ. 20, 576-588 (2013
152. Tovar, C. et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 73, 2587-2597 (2013
153. Ray-Coquard, I. et al. Effect of the MDM2 antagonist RG7112 on the p53 pathway in patients with MDM2 amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof of mechanism study. Lancet Oncol. 13, 1133-1140 (2012
154. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679-683 (2008
155. Carter, B. Z. et al. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 115, 306-314 (2010
156. Valentine, J. M., Kumar, S. & Moumen, A. A p53 independent role for the MDM2 antagonist Nutlin 3 in DNA damage response initiation. BMC Cancer 11, 79 (2011
157. Iancu-Rubin, C. et al. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Exp. Hematol. http://dx.doi.org/10.1016/j.exphem.2013. 11.012 (2013
158. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
159. Michaelis, M. et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin 3 results in the emergence of p53 mutated multi-drug-resistant cancer cells. Cell Death Dis. 2, e243 (2011
160. Aziz, M. H., Shen, H. & Maki, C. G. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin 3. Oncogene 30, 4678-4686 (2011
161. Jones, R. J., Bjorklund, C. C., Baladandayuthapani, V., Kuhn, D. J. & Orlowski, R. Z. Drug resistance to inhibitors of the human double minute 2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol. Cancer Ther. 11, 2243-2253 (2012
162. Brummelkamp, T. R. et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nature Chem. Biol. 2, 202-206 (2006
163. Shchors, K. et al. Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc. Natl Acad. Sci. USA 110, E1480-E1489 (2013
164. Rudin, C. M. et al. Phase II study of single-Agent navitoclax (ABT 263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163-3169 (2012
165. Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488-496 (2012
166. van Delft, M. F. et al. The BH3 mimetic ABT 737 targets selective Bcl 2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl 1 is neutralized. Cancer Cell 10, 389-399 (2006
167. Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT 737 in acute myeloid leukemia. Cancer Cell 10, 375-388 (2006
168. Yecies, D., Carlson, N. E., Deng, J. & Letai, A. Acquired resistance to ABT 737 in lymphoma cells that up regulate MCL 1 and BFL 1. Blood 115, 3304-3313 (2010
169. Rooswinkel, R. W., van de Kooij, B., Verheij, M. & Borst, J. Bcl 2 is a better ABT 737 target than Bcl xL or Bcl w and only Noxa overcomes resistance mediated by Mcl 1, Bfl 1, or Bcl B. Cell Death Dis. 3, e366 (2012
170. Lew, Q. J. et al. NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53 inducing anticancer compounds. Cell Cycle 10, 1978-1987 (2011
171. Kojima, K., Konopleva, M., Samudio, I. J., Ruvolo, V. & Andreeff, M. Mitogen-Activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res. 67, 3210-3219 (2007
172. Konopleva, M. et al. MEK inhibition enhances ABT 737 induced leukemia cell apoptosis via prevention of ERK-Activated MCL 1 induction and modulation of MCL 1/BIM complex. Leukemia 26, 778-787 (2012
173. Glaser, S. P. et al. Anti-Apoptotic Mcl 1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26, 120-125 (2012
174. Vo, T. T. et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151, 344-355 (2012
175. Ni Chonghaile, T. et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334, 1129-1133 (2011
176. Patton, J. T. et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin 3. Cancer Res. 66, 3169-3176 (2006
177. Wade, M., Wong, E. T., Tang, M., Stommel, J. M. & Wahl, G. M. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 281, 33036-33044 (2006
178. Garcia, D. et al. Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev. 25, 1746-1757 (2011
179. Wei, S. J. Inhibition of Nutlin-resistant HDM2 mutants by stapled peptides. PLoS ONE 8, e81068 (2013
180. Michaelis, M. et al. Reversal of P glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin 3. Cancer Res. 69, 416-421 (2009
181. Ribas, J., Boix, J. & Meijer, L. (R)-roscovitine (CYC202, seliciclib) sensitizes SH SY5Y neuroblastoma cells to nutlin 3 induced apoptosis. Exp. Cell Res. 312, 2394-2400 (2006
182. Cheok, C. F., Dey, A. & Lane, D. P. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: A potent drug combination. Mol. Cancer Res. 5, 1133-1145 (2007
183. Kojima, K., Konopleva, M., Tsao, T., Nakakuma, H. & Andreeff, M. Concomitant inhibition of Mdm2 p53 interaction and Aurora kinases activates the p53 dependent postmitotic checkpoints and synergistically induces p53 mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 112, 2886-2895 (2008
184. Cheok, C. F., Kua, N., Kaldis, P. & Lane, D. P. Combination of nutlin 3 and VX 680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-Type p53. Cell Death Differ. 17, 1486-1500 (2010
185. Coll-Mulet, L. et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B cell chronic lymphocytic leukemia cells. Blood 107, 4109-4114 (2006
186. Cao, C. et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol. Cancer Ther. 5, 411-417 (2006
187. Supiot, S., Hill, R. P. & Bristow, R. G. Nutlin 3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol. Cancer Ther. 7, 993-999 (2008
188. Zhang, W. et al. Blockade of mitogen-Activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces apoptosis in acute myeloid leukemia via BH3 only proteins Puma and Bim. Cancer Res. 70, 2424-2434 (2010
189. Thompson, T., Andreeff, M., Studzinski, G. P. & Vassilev, L. T. 1,25 dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin 3a in acute myeloid leukemia cells expressing wild-Type p53. Mol. Cancer Ther. 9, 1158-1168 (2010
190. McCormack, E. et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin 3 in acute myeloid leukemia. Leukemia 26, 910-917 (2012
191. Li, M., Luo, J., Brooks, C. L. & Gu, W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277, 50607-50611 (2002
192. Wade, M., Rodewald, L. W., Espinosa, J. M. & Wahl, G. M. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle 7, 1973-1982 (2008
193. Kojima, K. et al. Concomitant inhibition of MDM2 and Bcl 2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 5, 2778-2786 (2006
194. Mir, R. et al. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-Type ovarian cancer cells. Int. J. Cancer 132, 1525-1536 (2013
195. Tovar, C. et al. MDM2 antagonists boost antitumor effect of androgen withdrawal: Implications for therapy of prostate cancer. Mol. Cancer 10, 49 (2011
196. Konopleva, M. et al. Stromal cells prevent apoptosis of AML cells by up regulation of anti-Apoptotic proteins. Leukemia 16, 1713-1724 (2002
197. Davids, M. S. et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 120, 3501-3509 (2012
198. Sullivan, K. D. et al. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature Chem. Biol. 8, 646-654 (2012
199. Zauli, G. et al. Dasatinib plus Nutlin 3 shows synergistic antileukemic
200. Zauli, G. et al. The sorafenib plus nutlin 3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 97, 1722-1730 (2012
201. Lehmann, B. D. et al. A dominant role for p53 dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 6, 595-605 (2007
202. Blagosklonny, M. V. & Pardee, A. B. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 61, 4301-4305 (2001
203. Blagosklonny, M. V. & Pardee, A. B. The restriction point of the cell cycle. Cell Cycle 1, 103-110 (2002
204. Carvajal, D. et al. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 65, 1918-1924 (2005
205. Kranz, D. & Dobbelstein, M. Nongenotoxic p53 activation protects cells against S phase-specific chemotherapy. Cancer Res. 66, 10274-10280 (2006
206. Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15-16 (1992
207. van Leeuwen, I. M., Rao, B., Sachweh, M. C. & Lain, S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle 11, 1851-1861 (2012
208. van Leeuwen, I. M. Cyclotherapy: Opening a therapeutic window in cancer treatment. Oncotarget 3, 596-600 (2012
209. Sur, S. et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl Acad. Sci. USA 106, 3964-3969 (2009
210. Oda, K. et al. p53AIP1, a potential mediator of p53 dependent apoptosis, and its regulation by Ser 46 phosphorylated p53. Cell 102, 849-862 (2000
211. Chen, X. & Ko, L. J., Jayaraman, L. & Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451 (1996
212. Veprintsev, D. B. & Fersht, A. R. Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res. 36, 1589-1598 (2008
213. Schlereth, K. et al. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 38, 356-368 (2010
214. Schlereth, K., Charles, J. P., Bretz, A. C. & Stiewe, T. Life or death: 53 induced apoptosis requires DNA binding cooperativity. Cell Cycle 9, 4068-4076 (2010
215. Timofeev, O. et al. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep. 3, 1512-1525 (2013
216. Samuels-Lev, Y. et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8, 781-794 (2001
217. Bergamaschi, D. et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72 polymorphic p53. Nature Genet. 38, 1133-1141 (2006
218. Zhang, X., Wang, M., Zhou, C., Chen, S. & Wang, J. The expression of iASPP in acute leukemias. Leuk. Res. 29, 179-183 (2005
219. Jiang, L. et al. iASPP and chemoresistance in ovarian cancers: Effects on paclitaxel-mediated mitotic catastrophe. Clin. Cancer Res. 17, 6924-6933 (2011
220. Kruse, J. P. & Gu, W. Modes of p53 regulation. Cell 137, 609-622 (2009
221. Lane, D. P., Brown, C. J., Verma, C. & Cheok, C. F. New insights into p53 based therapy. Discov. Med. 12, 107-117 (2011
222. Gannon, H. S., Woda, B. A. & Jones, S. N. ATM phosphorylation of Mdm2 Ser394 regulates the amplitude and duration of the DNA damage response in mice. Cancer Cell 21, 668-679 (2012
223. Sakaguchi, K. et al. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1 like kinase. Effect on Mdm2 binding. J. Biol. Chem. 275, 9278-9283 (2000
224. D'Orazi, G. et al. Homeodomain-interacting protein kinase 2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nature Cell Biol. 4, 11-19 (2002
225. Hofmann, T. G. et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase 2. Nature Cell Biol. 4, 1-10 (2002
226. Ma, T. et al. Inability of p53 reactivating compounds Nutlin 3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation. Biochem. Biophys. Res. Commun. 417, 931-937 (2012
227. Henry, R. E., Andrysik, Z., Paris, R., Galbraith, M. D. & Espinosa, J. M. A. DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX. EMBO J. 31, 1266-1278 (2012
228. Michalak, E. M., Villunger, A., Adams, J. M. & Strasser, A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 15, 1019-1029 (2008
229. Happo, L. et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 116, 5256-5267 (2010
230. Chen, L. et al. Differential targeting of prosurvival Bcl 2 proteins by their BH3 only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403 (2005
231. Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11, 577-590 (2003
232. Chipuk, J. E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014 (2004
233. Lujambio, A. et al. Non-cell-Autonomous tumor suppression by p53. Cell 153, 449-460 (2013
234. Jackson, J. G. et al. p53 mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21, 793-806 (2012
235. Vassilev, L. T. Small-molecule antagonists of p53 MDM2 binding: Research tools and potential therapeutics. Cell Cycle 3, 419-421 (2004
236. Uoto, K. et al. Imidazothiazole derivative having 4,7 diazaspiro [2.5] octane ring structure. WO Patent 2009151069A1 (2009
237. Koblish, H. K. et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther. 5, 160-169 (2006
238. Secchiero, P., Vaccarezza, M., Gonelli, A. & Zauli, G. TNF-related apoptosis-inducing ligand (TRAIL): A potential candidate for combined treatment of hematological malignancies. Curr. Pharm. Des. 10, 3673-3681 (2004
239. Vatsyayan, R., Singhal, J., Nagaprashantha, L. D., Awasthi, S. & Singhal, S. S. Nutlin 3 enhances sorafenib efficacy in renal cell carcinoma. Mol. Carcinog. 52, 39-48 (2013
240. Kojima, K. et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121, 4166-4174 (2013